Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News RXi Pharmaceuticals Corp RXII

Healthcare Biotechnology
"RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs."

Recent & Breaking News (NDAQ:RXII)

Today's Reviews on APDN, FTTN, APPA and RXII

Accesswire November 14, 2013

RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery

PR Newswire November 13, 2013

RXi Pharmaceuticals' Valuation Moves From Product To Platform

Accesswire November 12, 2013

New Small Cap Reports on RXII, APPA and TRTC

Accesswire November 1, 2013

3 Reasons To Consider Investing In RXi Pharmaceuticals

Accesswire October 16, 2013

New Breakthroughs Bolster RNAi Stocks

Accesswire September 24, 2013

RXi Pharmaceuticals to Present at the 12th Annual BIO Investor Forum

PR Newswire September 17, 2013

Exploring RXi Pharmaceuticals Clinical Pipeline

Accesswire August 7, 2013

RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split

PR Newswire July 22, 2013

RXi Pharmaceuticals Announces CEO Interview

PR Newswire July 18, 2013

RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study

PR Newswire July 12, 2013

RNAi Therapeutics Make Progress Across the Board

Accesswire June 26, 2013

RXi Pharmaceuticals Corporation Begins Trading on OTCQX®

PR Newswire June 19, 2013

RXi Pharmaceuticals (RXII) Shares to Begin Trading on OTCQX®

Accesswire June 19, 2013

RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study in Healthy Volunteers with RXI-109

PR Newswire June 6, 2013

Nobel Prize Winner's RNA Stock Takes Off

Accesswire June 4, 2013

Investors Begin To Realize RNA's Potential

Accesswire May 21, 2013

RXi Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference

PR Newswire May 20, 2013

RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2013

Marketwired May 15, 2013

VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results

Globe Newswire May 9, 2013